Diurnal Group plc operates as a specialty pharmaceutical company. The company develops hormone therapeutics for the treatment of rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort that is in Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; Rheumacor for the treatment of inflammatory diseases; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism; and siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent cushing's syndrome. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
SymbolLON:DNL
CUSIPN/A
Phone+44-29-20682069
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-39.52%
Return on Assets-29.56%
Miscellaneous
EmployeesN/A
Outstanding Shares52,320,000
Market Cap£160.17 million
Diurnal Group (LON:DNL) Frequently Asked Questions
What is Diurnal Group's stock symbol?
Diurnal Group trades on the London Stock Exchange (LON) under the ticker symbol "DNL."
How were Diurnal Group's earnings last quarter?
Diurnal Group PLC (LON:DNL) issued its quarterly earnings data on Monday, March, 12th. The company reported ($12.70) earnings per share (EPS) for the quarter. View Diurnal Group's Earnings History.
What price target have analysts set for DNL?
1 Wall Street analysts have issued twelve-month target prices for Diurnal Group's stock. Their predictions range from GBX 185 to GBX 185. On average, they expect Diurnal Group's share price to reach GBX 185 in the next twelve months. This suggests a possible upside of 10.4% from the stock's current price. View Analyst Price Targets for Diurnal Group.
What is the consensus analysts' recommendation for Diurnal Group?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diurnal Group in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Diurnal Group.
Who are some of Diurnal Group's key competitors?
Some companies that are related to Diurnal Group include OrganiGram (OGI), Supreme Cannabis (FIRE), Weed (BUDZ), OrganiGram (OGRMF), Medical Marijuana (MJNA), Benchmark (BMK), MPX Bioceutical (MPX), ICC Labs (ICC), WeedMD (WMD), Cannabis Science (CBIS), Biosyent (RX), Cipher Pharmaceuticals (CPH), Cipher Pharmaceuticals (CPHRF), Marijuana Company Of America (MCOA) and Amryt Pharma (AMYT).
Who are Diurnal Group's key executives?
Diurnal Group's management team includes the folowing people:
- Dr. Martin Whitaker, CEO & Exec. Director
- Prof. Richard Ross, Chief Scientific Officer & Exec. Director
- Mr. Richard Edward Bungay BSc, ACA, Chief Financial Officer and Director (Age 49)
- Mr. Michael Withe, Commercial Director
- Mr. John Porter MBBS, Ph.D., Medical Affairs Director
Has Diurnal Group been receiving favorable news coverage?
News coverage about DNL stock has trended positive recently, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Diurnal Group earned a daily sentiment score of 0.28 on Accern's scale. They also assigned news stories about the company an impact score of 48.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Diurnal Group.
How do I buy shares of Diurnal Group?
Shares of DNL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Diurnal Group's stock price today?
One share of DNL stock can currently be purchased for approximately GBX 167.50.
How big of a company is Diurnal Group?
Diurnal Group has a market capitalization of £160.17 million.
How can I contact Diurnal Group?
Diurnal Group's mailing address is Heath Park, CARDIFF, CF14 4UJ, United Kingdom. The company can be reached via phone at +44-29-20682069.
MarketBeat Community Rating for Diurnal Group (LON DNL)
MarketBeat's community ratings are surveys of what our community members think about Diurnal Group and other stocks. Vote "Outperform" if you believe DNL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNL will underperform the S&P 500 over the long term. You may vote once every thirty days.
